Identifying enzymes regulating protein synthesis in ... inhibiting SMYD5 made the mice more susceptible to targeted therapy treatment, such as chimeric antigen receptor (CAR)-T therapy, where ...

The Lysosomal Storage Disorders Support Society of India (LSDSS), a support group advocating for rare-disease patients, has ...

Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosisDesignation is based on ...

Request To Download Free Sample of This Strategic Report @ Pompe disease, a rare genetic disorder, poses significant challenges for patients and healthcare providers in Saudi Arabia. With its diverse ...

A new kind of cancer gene therapy can be remotely activated at a specific part of the body. The team developed a version of ...

A study in mice offers evidence that inhibiting EZH2 can enhance lymphoma immunogenicity and overcome CAR-T cell therapy resistance.

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib for the treatment of adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS).

Researchers reveal that metabolic enzymes known for their roles in energy production and nucleotide synthesis are taking on unexpected 'second jobs' within the nucleus, orchestrating critical ...

Researchers founded Rarity PBC as a public benefit corporation that will license the IP and develop operations to potentially ...

This is a crucial step in order to make gene therapy more effective and to increase the number of patients able to access it.

In a single IV injection, a gene therapy targeting cBIN1 can reverse the effects of heart failure and restore heart function in a large animal model. The therapy increases the amount of blood the ...

An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate ... “Overcoming resistance to therapy is a major challenge in castration-resistant ...